• About
    • Who We Are
    • Core Values
    • Leadership
    • Partners
    • Intellia’s Journey
  • Our Science
    • What is CRISPR?
    • CRISPR Videos
    • Full-Spectrum Approach
    • Scientific Publications & Presentations
    • Glossary
  • Programs & Pipelines
    • Pipeline
    • Clinical Trials
  • Patient Stories
    • Patient Stories
    • Disease Focus
      • Overview
      • Transthyretin Amyloidosis
      • Hereditary Angioedema
      • Alpha-1 Antitrypsin Deficiency
      • Hodgkin Lymphoma
  • Investors & Media
    • Overview
    • Press Releases
    • Scientific Publications & Presentations
    • Corporate Deck
    • Events & Presentations
    • Press Kit
    • Corporate Governance
    • Financial Info
    • Stock Info
    • Analyst Coverage
    • Investor Resources
  • Careers
    • Life @ Intellia
    • Join Us
  • Full-Spectrum Blog
  • Contact
Intellia Therapeutics
  • Full-Spectrum Blog
  • Contact
  • About
    • Who We Are
    • Core Values
    • Leadership
    • Partners
    • Intellia’s Journey
  • Our Science
    • What is CRISPR?
    • CRISPR Videos
    • Full-Spectrum Approach
    • Scientific Publications &
      Presentations
    • Glossary
  • Programs & Pipelines
    • Pipeline
    • Clinical Trials
  • Patient Focus
    • Patient Stories
    • Disease Focus
  • Investors & Media
    • Overview
    • Press Releases
    • Scientific Publications &
      Presentations
    • Corporate Deck
    • Events & Presentations
    • Press Kit
    • Corporate Governance
    • Financial Info
    • Stock Info
    • Analyst Coverage
    • Investor Resources
  • Careers
    • Life @ Intellia
    • Join Us
Patient Stories

Patient Stories

  • Patient Stories
  • Disease Focus

Conventional medicines treat the symptoms instead of the cause of diseases, meaning that patients must be treated throughout their lives. We are working to develop one-time treatments that target the cause of diseases.

Patients Are Counting on Us

image

Milton, living with ATTR amyloidosis with cardiomyopathy

Read more
image
Oren, Shanna and Damian, living with hereditary angioedema type 1
Read more
image
Nancy, living with ATTR amyloidosis with polyneuropathy
Read more
image

Carlos, David and Vince launched UKATPA to educate and support patients, doctors and caregivers.

Read more
image
Bill and Maura share their journey about Bill’s diagnosis with transthyretin (ATTR) amyloidosis.
Read more
  • Cookie Policy
  • Terms of Use
  • Privacy Policy

© Intellia Therapeutics, Inc. 2023

Intellia Therapeutics and the Intellia Therapeutics logo are registered trademarks with the U.S. Patent & Trademark Office.

You are leaving the
Intellia Therapeutics, Inc. website.

You may return to the Intellia Therapeutics, Inc. website by closing the window to the third-party website you have opened. Do you wish to continue?

When you are ready to return to the Intellia Therapeutics, Inc. website, simply close the window to the third-party website you have opened.

Yes No